Navigation Links
Barr Reports GAAP Earnings of $1.18 Per Share for 2007 and $0.30 Per Share for the Fourth Quarter; Adjusted Earnings Were $3.16 Per Share for 2007 and $0.79 Per Share for the Fourth Quarter
Date:2/28/2008

MONTVALE, N.J., Feb. 28 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. (NYSE: BRL) today reported net earnings of $128.4 million, or $1.18 per share, for the year ended December 31, 2007 on revenues of $2.5 billion. On a non-GAAP basis, adjusted earnings per share were $3.16 for 2007. A reconciliation of GAAP-based earnings per share to adjusted earnings per share is presented in the table at the end of this press release. For the fourth quarter ended December 31, 2007, net earnings were $32.5 million, or $0.30 per share, on revenues of $668.7 million. On a non-GAAP basis, adjusted earnings per share were $0.79 for the quarter.

In the fourth quarter of calendar 2006, Barr changed its fiscal year end from June 30th to December 31st, effective December 31, 2006. In addition, on October 24, 2006, Barr acquired PLIVA d.d., a Croatian generics pharmaceutical company, for approximately $2.4 billion. As a result of these two events, the comparison of information for the year ended December 31, 2007 and the 12- month period ended December 31, 2006, which is unaudited, is not very meaningful. In this release, "2007" refers to Barr's calendar year ended December 31, 2007, and "2006" refers to the 12-month period ended December 31, 2006 and includes PLIVA's results from October 25, 2006 through December 31, 2006.

"I am pleased to report strong revenue growth across the Company in 2007, driven by proprietary and U.S. generic sales, as well as sound results in our international markets. In addition, during the year we invested a record $248 million in new product development, and filed a record 30 ANDAs and three NDAs in the United States. These are exceptional results for our Company, particularly given that significant management rite-off of acquired IPR&D - 4,601

Earnings (loss) from operations 74,010 312,645

Interest income 6,158 33,359

Interest expense 36,401 158,882

Other (expense) income 9,036 20,713

Earnings (loss) before income taxes

and minority interest 52,803 207,835

Income tax expense 14,850 64,546

Minority interest 498 (1,164)

Net earnings from continuing

operations 38,451 142,125

Discontinued operations

Loss from discontinued operations,

net of taxes (5,368) (13,164)

Loss on disposal of discontinued

operations, net of taxes (575) (611)

Net loss from discontinued

operations, net of tax (5,943) (13,775)

Net earnings $32,508 $128,350

Earnings per common share - diluted:

Earnings (loss) per common share -

continuing operations $0.35 $1.31

Earnings (loss) per common share -

discontinued operations $(0.05) $(0.13)

Net earnings per common share -

diluted $0.30 $1.18

Weighted average shares - assuming

dilution 109,236 108,631

Stock-based compensation expense:

Cost of sales $1,283 $8,006

Selling, general and administrative 2,421 15,129

Research and development 667 4,615

Total stock-based compensation expense $4,371 $27,750

As of As of

December 31, December 31,

2007 2006

Cash & cash equivalents $246,492 $231,975

Marketable securities - current and

long-term 304,543 682,692

Accounts receivable 496,636 511,136

Other receivables 86,048 67,462

Inventory 501,207 426,270

Accounts payable & accrued liabilities 442,193 408,763

Working capital 970,854 876,106

Total assets 4,761,627 4,961,862

Total debt 2,079,757 2,677,668

Shareholders' equity 1,866,321 1,465,228

Reconciliation of Adjusted Earnings to GAAP Earnings; EBITDA

To supplement its consolidated financial statements presented in accordance with accounting principles generally accepted in the United States of America ("GAAP"), the Company is providing the supplemental financial information contained below to reflect (1) the adjusted earnings per share effect of certain unusual or infrequent charges or benefits that were taken or received in the year and quarter ended December 31, 2007, and (2) the calculation of EBITDA for each period presented.

Adjusted earnings per share and EBITDA are non-GAAP financial measures. The Company is providing this information, however, because it believes that such information is useful to both management and investors in that it facilitates analysis by both management and investors in evaluating the Company's performance and trends. The presentation of this additional information is not meant to be considered in isolation of, or as a substitute for, results prepared in accordance with GAAP.

Barr Pharmaceuticals, Inc. Selected Adjusted Financial Data

(in thousands, except per share amounts)

Three Months Ended December 31, 2007

Adjusted

GAAP Adjustments Earnings

Revenues:

Product sales $628,363 $- $628,363

Alliance and development

revenue 28,318 - 28,318

Other revenue 12,012 - 12,012

Total revenues 668,693 - 668,693

Costs and expenses:

Cost of sales 326,435 (60,046)(c)(d)(e)(f) 266,389

Selling, general and

administrative 206,599 (3,117)(c)(d)(e) 203,482

Research and development 61,649 (837)(c)(d)(e) 60,812

Earnings from operations 74,010 64,000 138,010

Interest income 6,158 - 6,158

Interest expense 36,401 - 36,401

Other income (expense), net 9,036 - 9,036

Earnings before income taxes

and minority interest 52,803 64,000 1,734 118,537

Income tax expense 14,850 18,149 (g) 32,999

Minority interest 498 (91) (33) 375

Net earnings from continuing

operations 38,451 45,760 1,701(b) 85,912

Loss from discontinued

operations, net of taxes (5,943) 5,943(a) -

Net earnings $32,508 $51,703 $1,701 $85,912

Diluted

Earnings per common share -

continuing operations $0.35 $0.79

Earnings per common share -

discontinued operations $(0.05) $-

Net earnings per common

share - diluted $0.30 $0.79

Weighted average shares -

diluted 109,236 109,236

Summary Of Adjustment Items:

Three Months

Ended Dec 31, 2007

(a) In order to provide investors and management

a basis to evaluate the performance of the

ongoing operations, adjusted earnings exclude

the impact of the loss from discontinued operations

Accounted for as discontinued operations $5,943

(b) Net loss from operations expected to be divested,

net of minority interest $(1,701)

To account for losses associated with our non-core

DDDI business which is expected to be divested.

The Company believes adjusting GAAP earnings for

this loss will allow investors to better assess

our ongoing activities.

(c) Amortization and inventory step up adjustments:

Cost of sales (40,301)

Selling, general and administrative (340)

Research and development (27)

Total $(40,668)

(d) Incremental PLIVA Depreciation due to purchase

accounting write up of fixed assets:

Cost of sales (4,739)

Selling, general and administrative (357)

Research and development (142)

Total $(5,238)

(e) Stock option expense:

Cost of sales $(1,283)

Selling, general and administrative (2,420)

Research and development (668)

Total (4,371)

(f) Product Royalty contingency $(13,723)

(g) Adjustments to tax expense, including:

Tax impact of adjustments (a) - (f) above. $20,774

Tax (benefit) from recognition of acquired NOL (2,625)

Total $18,149

EBITDA (from continuing operations) Calculation:

Three Months

Ended Dec 31, 2007

Earnings from operations $74,010

Depreciation 33,694

Amortization 40,699

EBITDA $148,403

Barr Pharmaceuticals, Inc. Selected Adjusted Financial Data

(in thousands, except per share amounts)

Twelve Months Ended December 31, 2007

Adjusted

GAAP Adjustments Earnings

Revenues:

Product sales $2,334,136 $- $2,334,136

Alliance and development

revenue 121,858 - 121,858

Other revenue 44,588 - 44,588

Total revenues 2,500,582 - 2,500,582

Costs and expenses:

Cost of sales 1,171,099 (233,529)(c)(d)(e)(h) 937,570

Selling, general

and administrative 763,784 (33,367)(c)(d)(e)(g) 730,417

Research and development 248,453 (5,300)(c)(d)(e) 243,153

Write-off of

acquired IPR&D 4,601 (4,601)(f) -

Earnings from operations 312,645 276,797 589,442

Interest income 33,359 - 33,359

Interest expense 158,882 - 158,882

Other income (expense), net 20,713 - 20,713

Earnings before income taxes

and minority interest 207,835 276,797 4,053 488,685

Income tax expense 64,546 79,414 (i) 143,960

Minority interest (1,164) (374) (82) (1,620)

Net earnings from

continuing operations 142,125 197,010 3,971(b) 343,106

Loss from discontinued

operations, net of taxes (13,775) 13,775 (a) -

Net earnings $128,350 $210,785 $3,971 $343,106

Diluted

Earnings per common share

- continuing operations $1.31 $3.16

Earnings per common share -

discontinued operations $(0.13) $-

Net earnings per common

share - diluted $1.18 $3.16

Weighted average

shares - diluted 108,631 108,631

Summary Of Adjustment Items:

Twelve Months

Ended Dec 31, 2007

(a) In order to provide investors and management

a basis to evaluate the performance of the

ongoing operations, adjusted earnings exclude

the impact of the loss from discontinued operations

Accounted for as discontinued operations $13,775

(b) Net loss from operations expected to be divested,

net of minority interest $(3,971)

To account for losses associated with our non-core

DDDI business which is expected to be divested.

The Company believes adjusting GAAP earnings for

this loss will allow investors to better assess our

ongoing activities.

(c) Amortization and inventory step up adjustments:

Cost of sales (193,769)

Selling, general and administrative (1,399)

Research and development (95)

Total $(195,263)

(d) Incremental PLIVA Depreciation due to purchase

accounting write up of fixed assets:

Cost of sales $(18,031)

Selling, general and administrative (1,590)

Research and development (589)

Total $(20,210)

(e) Stock option expense:

Cost of sales $(8,006)

Selling, general and administrative (15,128)

Research and development (4,616)

Total $(27,750)

(f) Write off of acquired IPR&D associated with

additional PLIVA shares $(4,601)

(g) Estimated reserve for litigation charged to SG&A $(15,250)

(h) Product Royalty contingency $(13,723)

(i) Adjustments to tax expense, including:

Tax impact of adjustments (a) - (h) above $80,238

Tax (benefit) from recognition of acquired NOL (10,400)

Impact of favorable change in German tax rate 9,575

Total $79,414

EBITDA (from continuing operations) Calculation:

Twelve Months

Ended Dec 31, 2007

Earnings from operations $312,645

Depreciation 127,971

Amortization 166,688

EBITDA $607,304

resources were devoted to the successful completion of our major short-term integration goals following the PLIVA acquisition," said Bruce L. Downey, Barr's Chairman and Chief Executive Officer.

"As part of the integration of Barr and PLIVA, we met our short-term goals of completing the global management restructuring, consolidating the PLIVA U.S. operations into Barr, divesting non-strategic operations in Spain and Italy, completing the IPO of our non-strategic Veterina business, and expanding our presence in the significant German specialty pharmaceutical market with the acquisition of O.R.C.A.pharm in September 2007. We reported the highest revenues in our history for our generic oral contraceptive and proprietary portfolios, with proprietary sales led by sales of Plan B(TM) and ParaGard(R). We also initiated a record 11 U.S. patent challenge cases, and completed the patent challenge trial related to the Yasmin(R) oral contraceptive. Individually, these accomplishments represent the core strengths of our business. Combined, they speak to the significant opportunities the combination of Barr and PLIVA has created for long-term growth and success."

Revenues

Generic Product Sales

Sales of the Company's generic products were $506 million in the fourth quarter of 2007 and $1.9 billion for 2007, both reflecting significant increases over the prior year periods mainly due to the PLIVA acquisition. A discussion of the Company's generic product sales for the fourth quarter of 2007 compared to the prior year period is presented below.

U.S. Generic Sales

Sales of U.S. generic products totaled $310 million for the fourth quarter of 2007, compared to $298 million in the prior year period. The increase in sales is primarily related to the full quarter impact of sales of PLIVA's U.S. product line in 2007, including Azithromycin. These products are now being sold under the Barr label.

Sales of generic oral contraceptives, the Company's largest single category of generic products, were $118 million for the fourth quarter of 2007, compared to $114 million in the prior year period. The Company launched its 25th generic oral contraceptive product, TriLegest(TM) during the fourth quarter of 2007.

Europe and Rest of the World ("ROW") Generic Sales

Sales of generic products in Europe and the ROW through our PLIVA subsidiary were $196 million in the fourth quarter of 2007. Revenues were primarily driven by sales of PLIVA products in the key markets of Germany, Croatia, Poland and Russia. Prior to the Company's acquisition of PLIVA in October 2006, Barr did not have any product sales in Europe or the ROW.

Proprietary Product Sales

The Company's proprietary product sales were $438 million for 2007, up 12% compared to $391 million in 2006. The increase was primarily attributable to higher sales of Plan B Over-the-Counter/Rx, Adderall(R) IR and SEASONIQUE(R) extended-cycle oral contraceptive, all of which were launched in the second half of 2006. These increases more than offset lower sales of SEASONALE(R) extended-cycle oral contraceptive, which faced generic competition in September 2006 following the expiration of three years of market exclusivity.

For the fourth quarter of 2007, proprietary product sales were $122 million, compared to $98 million in the prior year period. The increase was primarily attributable to higher sales of Plan B and SEASONIQUE and more than offset the expected lower sales of SEASONALE.

Alliance and Development Revenue

During 2007, the Company reported alliance and development revenue of $122 million, compared to $131 million in 2006. For the fourth quarter of 2007, alliance and development revenue was $28 million, as compared to $34 million in the prior year period. The decrease for the year and for the fourth quarter ended December 31, 2007 primarily reflects a decline in income derived from the Company's share of the profits from sales of fexofenadine hydrochloride tablets from Teva, which began in September 2005, and lower income from the royalty earned under its April 2005 agreements with Kos Pharmaceuticals relating to the Niaspan(R) and Advicor(R) cholesterol lowering agents. These declines were partially offset by an increase in royalties and other fees received under the Company's agreements with Shire plc.

Other Revenue

Other revenue primarily includes revenue from non-core operations acquired in connection with the PLIVA acquisition, including the diagnostic, disinfectants, dialysis and infusions business. Other revenue totaled $45 million for calendar 2007 and $12 million for the fourth quarter of 2007.

Margins

Generic: Margins in the generic segment were 47% for both the quarter and year ended December 31, 2007.

Proprietary: Margins in the proprietary segment for the quarter and year ended December 31, 2007 were 55% and 68%, respectively. Proprietary margins for the fourth quarter ended December 31, 2007 were negatively impacted by a $13.7 million, or $0.08 per share, charge related to a product royalty contingency agreement for the Company's Cenestin(R) product.

Update on R&D Activities

Research and development investment for the quarter and year ended December 31, 2007 totaled $62 million and $248 million, respectively.

Generic Products

During 2007, the Company filed 30 Abbreviated New Drug Applications (ANDAs), resulting in approximately 70 ANDAs, including tentatively approved applications pending at the U.S. Food and Drug Administration (FDA) at the end of the year. These ANDAs target branded pharmaceutical products with an estimated $29 billion in annual sales. The Company also filed 224 product registrations, representing 65 molecules with regulatory bodies in Europe and in the ROW during 2007, resulting in 287 product registrations, representing 90 molecules pending with regulatory bodies in Europe and in the ROW at year end.

During the fourth quarter of 2007, the Company received six generic product approvals in the U.S. from the FDA, including tentative approvals, and 39 approvals, representing 28 molecules, from regulatory bodies in Europe and in the ROW.

Proprietary Products

The Company currently has an extensive proprietary clinical development program that includes four products in Phase III studies and three New Drug Applications pending at the FDA.

Selling, General and Administrative

The Company's SG&A expenses for the quarter and year ended December 31, 2007 totaled $207 million and $764 million, respectively. SG&A for 2007 included a charge of $15.3 million for litigation related to the Ovcon(R) oral contraceptive product.

Interest Expense/Income and Other Income

During 2007, the Company recorded $159 million of interest expense, almost all of which is related to interest on the debt incurred in connection with the PLIVA acquisition. In addition, during 2007, the Company recorded interest income of $33 million and other income of $21 million.

Stock-Based Compensation

During 2007, the Company recorded stock-based compensation expenses of $27.8 million, or $0.17 per share. For the fourth quarter of 2007, the Company recorded stock-based compensation expenses of $4.4 million, or $0.03 per share. The impact of stock-based compensation for the year and quarter ended December 31, 2007 is allocated among cost of sales, SG&A and R&D.

Tax Rate

The Company's tax rate for the quarter and year ended December 31, 2007 was 28.1% and 31.1%, respectively. The tax rate for the year includes a one- time $9.6 million benefit from a reduction in deferred income taxes as a result of Germany's enactment of a lower corporate income tax rate.

Balance Sheet

The Company's cash, cash equivalents and marketable securities totaled approximately $551 million. At December 31, 2007, the Company had debt of $2.1 billion, down approximately $600 million from December 31, 2006.

EBITDA

Earnings from continuing operations before interest, taxes, depreciation and amortization (EBITDA), for the quarter and the year ended December 31, 2007 totaled $148 million and $607 million, respectively. Please see the reconciliation table at the end of this press release for the calculation of EBITDA.

2008 Financial Outlook

The Company expects adjusted earnings per fully diluted share for 2008 to be in the range of approximately $3.05 - $3.35. The adjustments are discussed in the paragraph immediately below. The Company expects total revenues for 2008 to be in the range of $2.7 - $2.8 billion, including total product sales in the range of $2.55 - $2.65 billion. On the expense side for 2008, the Company expects R&D investment of approximately $265 - $280 million, and SG&A expenses to be approximately $810 - $830 million.

The Company's adjusted earnings guidance for 2008 excludes the impact of amortization costs associated with acquired products, contributions and/or losses from the DDDI operations that the Company plans to divest and incremental depreciation related to purchase accounting. The Company's adjusted guidance also excludes the impact of any unscheduled launches resulting from patent challenges, other business development activities, and refinancing activities that may be completed after the date hereof and on or before December 31, 2008. In contrast to 2007, the Company's adjusted earnings guidance for 2008 does not add back stock compensation expense. The change in the Company's presentation of adjusted earnings results in a reduction of the estimated earnings for 2008 by approximately $0.20 per share.

Conference Call/Webcast

The Company will host a conference call at 8:30AM Eastern time on Thursday, February 28 to discuss results for the quarter and year ended December 31, 2007. The number to call from within the United States is: (877) 777-1973 and (612) 338- 1040 Internationally. A replay of the conference call will be available from 10:30AM Eastern time on February 28 through 11:59PM Eastern time March 6 and can be accessed by dialing (800) 475-6701 in the United States or (320) 365- 3844 Internationally and using the access code 906084.

The conference call will also be webcast live on the Internet. Investors and other interested parties may access the live webcast through the Investors section, under Calendar of Events, on Barr's website at http://www.barrlabs.com. Log on at least 15 minutes before the call begins to register and download or install any necessary audio software.

About Barr Pharmaceuticals, Inc.

Barr Pharmaceuticals, Inc. is a global specialty pharmaceutical company that operates in more than 30 countries worldwide and is engaged in the development, manufacture and marketing of generic and proprietary pharmaceuticals, biopharmaceuticals and active pharmaceutical ingredients. A holding company, Barr operates through its principal subsidiaries Barr Laboratories, Inc., Duramed Pharmaceuticals, Inc. and PLIVA d.d. The Barr group of companies markets more than 120 generic and 26 proprietary products in the U.S. and more than 1,200 products globally outside of the U.S. For more information, visit http://www.barrlabs.com.

Forward-Looking Statements

Except for the historical information contained herein, the statements made in this press release constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements can be identified by their use of words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates" and other words of similar meaning. Because such statements inherently involve risks and uncertainties that cannot be predicted or quantified, actual results may differ materially from those expressed or implied by such forward-looking statements depending upon a number of factors affecting the Company's business. These factors include, among others: the difficulty in predicting the timing and outcome of legal proceedings, including patent-related matters such as patent challenge settlements and patent infringement cases; the outcome of litigation arising from challenging the validity or non- infringement of patents covering our products; the difficulty of predicting the timing of FDA approvals; court and FDA decisions on exclusivity periods; the ability of competitors to extend exclusivity periods for their products; our ability to complete product development activities in the timeframes and for the costs we expect; market and customer acceptance and demand for our pharmaceutical products; our dependence on revenues from significant customers; reimbursement policies of third party payors; our dependence on revenues from significant products; the use of estimates in the preparation of our financial statements; the impact of competitive products and pricing on products, including the launch of authorized generics; the ability to launch new products in the timeframes we expect; the availability of raw materials; the availability of any product we purchase and sell as a distributor; the regulatory environment in the markets where we operate; our exposure to product liability and other lawsuits and contingencies; the increasing cost of insurance and the availability of product liability insurance coverage; our timely and successful completion of strategic initiatives, including integrating companies (such as PLIVA d.d.) and products we acquire and implementing our new SAP enterprise resource planning system; fluctuations in operating results, including the effects on such results from spending for research and development, sales and marketing activities and patent challenge activities; the inherent uncertainty associated with financial projections; our expansion into international markets through our PLIVA acquisition, and the resulting currency, governmental, regulatory and other risks involved with international operations; our ability to service our significantly increased debt obligations as a result of the PLIVA acquisition; changes in generally accepted accounting principles; and other risks detailed in our SEC filings, including in our Annual Report on Form 10-K for the year ended December 31, 2007.

The forward-looking statements contained in this press release speak only as of the date the statement was made. The Company undertakes no obligation (nor does it intend) to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required under applicable law.

Barr Pharmaceuticals, Inc. Selected Financial Data

(in thousands, except per share amounts)

Three Months Twelve Months

Ended Ended

December 31, December 31,

2007 2007

Revenues:

Product sales $628,363 $2,334,136

Alliance and development revenue 28,318 121,858

Other revenue 12,012 44,588

Total revenues 668,693 2,500,582

Costs and expenses:

Cost of sales 326,435 1,171,099

Selling, general and administrative 206,599 763,784

Research and development 61,649 248,453

W
'/>"/>

SOURCE Barr Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. QMed, Inc. Reports July Medicare SNP Enrollments
3. Phlo Affiliate Reports Expanded Coverage to Oregon Border
4. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
5. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
6. Carrington Reports Second Quarter 2007 Results
7. Avitar Reports Third Quarter Financial Results for Fiscal 2007
8. Response Genetics Reports Second Quarter 2007 Financial Results
9. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
10. Transgenomic, Inc. Reports Second Quarter 2007 Results
11. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... 12, 2016  BD (Becton, Dickinson and Company) (NYSE: ... today announced the launch of the BD CLiC™ System ... (AGBT) Meeting. --> ... by providing cost effective NGS library preparation with limited ... fully integrated, next generation sequencing (NGS) library prep instrument, ...
(Date:2/11/2016)... DIEGO, Feb. 11, 2016  Neurocrine Biosciences, Inc. (NASDAQ: NBIX ... ended December 31, 2015. --> ... a net loss of $29.3 million, or $0.34 loss per share, ... per share for the same period in 2014. For the year ... $88.9 million, or $1.05 loss per share, as compared to a ...
(Date:2/11/2016)... ATLANTA , Feb. 11, 2016  Spectra BioPharma ... Organization (CSO) that provides biopharma companies the experience, ... implement and deploy outsourced sales teams. Created in ... team addresses both the strategic and tactical needs ... innovative sales solutions through both personal and non-personal ...
(Date:2/11/2016)... BEACH, Florida , February 11, 2016 /PRNewswire/ ... PositiveID Corporation ("PositiveID" or "Company") (OTCQB: PSID), ... diagnostics, announced today that its Thermomedics subsidiary, which ... progress on its growth plan in January 2016, ... products distributors, increasing sequential monthly sales growth, and ...
Breaking Biology Technology:
(Date:2/5/2016)... 2016 http://www.researchandmarkets.com/research/5kvw8m/global_facial ) ... "Global Facial Recognition Market 2016-2020" report ... ) has announced the addition of the ... report to their offering. --> ... announced the addition of the "Global ...
(Date:2/3/2016)... , Feb. 3, 2016 Vigilant Solutions ... Police Department in Missouri solved ... plate reader (LPR) data from Vigilant Solutions. ... case in which the victim was walking out of a convenience store and ... space next to his vehicle, striking his vehicle and ...
(Date:2/2/2016)... , Feb. 2, 2016 Checkpoint ... that Rising Market Are you interested in ... forecasts revenues for checkpoint inhibitors. Visiongain,s report gives ... submarket, product and national level. Avoid falling ... what progress, opportunities and revenues those emerging cancer ...
Breaking Biology News(10 mins):